Revance Therapeutics 10-Q (11/8/22)

Impact to DAXXIFY: “ It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry… Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of, or affect the price that we may charge for, DAXXIFY™, or any future product candidates including an onabotulinumtoxinA biosimilar”

Scroll to Top